Prognostic Impact of AJCC Response Criteria for Neoadjuvant Chemotherapy in Stage II/III Breast Cancer Patients: Breast Cancer Subtype Analyses

The American Joint Committee on Cancer (AJCC) response criteria represent a simple and easily reproducible tool for response evaluation of patients on neoadjuvant therapy and a useful clinical prognostic marker for relapse-free survival (RFS). These criteria also have a prognostic impact in all four breast cancer subtypes, including luminal A in which pathologic complete response (pCR) has a limited role.

 BioMed Central Cancer

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.